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Previously we have shown that bovine bone (BB) 
gelatin stimulated proliferation of murine spleen 
cells in vitro [1]. BB and porcine skin (PS) gelatins 
stimulated murine peritoneal macrophages (mPMs) 
to secrete several cyokines, e. g., interleukin (IL)-6, 
IL-12, TNF-α and MCP-1 [2]. PS gelatin suppressed 
proliferation of cells of human as well as murine cell 
lines [1, 3, 4]. Recently we observed that PS gela-
tin stimulated murine anti-tumor peritoneal mac-
rophages [5]. The ability of PS gelatin to induce 
anti-tumor peritoneal macrophages was greater than 
LPS or interferon-γ (IFN-γ). In this study, we investi-
gated whether or not three kinds of gelatin including 
PS gelatin exerted anti-tumor activity in vivo.
MATERIALS AND METHODS
Mice. Five to eight week-old female C3H/HeN 
mice and Balb/c mice were purchased from Chubu 
Kagaku Shizai Co. Ltd. (Nagoya, Japan). The care 
of the animals used in this study was in compliance 
with the guideline of Aichi-Gakuin University.
Cell lines. A hepatic cell carcinoma cell line of C3H/
HeN mice, MH134 has been maintained in suspension 
culture in our laboratory and a N-nitroso-N-methy-
lurea-induced colon undifferentiated carcinoma cell 
line of BALB/c mice, Colon 26 has been maintained 
in monolayer culture.
Reagents. PS (Code No.G-6144) and bovine skin 
(BS) (Code No.G-6650) gelatin were purchased from 
Sigma Chemical Co. (St.Louis, MO, USA). BB gelatin 
(Code No.076-02765) was purchased from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan).
Preparation of peritoneal macrophages. Three 
mice, each was injected with 3 ml of 3% thioglycol-
late medium intraperitoneally (i. p.) on day or with 
12.5 mg of PS gelatin (0.5 ml) on day 0,1 and 2. 
On day 3, Peritoneal exudate cells (PECs) were 
collected by means of peritoneal lavage with phos-
phate buffered saline (PBS). They were incubated 
in 10%FCS modified MEM at 37° for 90 min. Modified 
MEM was composed of 2 mM L-glutamine, 5 x 10–5 M 
2-mercaptoethanol, 25 mM HEPES and Eagle’s mini-
mum essential medium (Nissui Pharmaceutical Co. 
Ltd., Tokyo, Japan ). Approximately 90% of the adhe-
rent cells were F4/80 (macrophage marker)-positive 
[5]. The adherent PECs were used as mPMs.
Anti-tumor activity of peritoneal macrophages 
or gelatin in vitro. Anti-tumor activity of peritoneal 
macrophages in vitro was estimated as described else-
where [5]. Briefly, MH134 cells (5 x 103/well) were incu-
bated with 1 x 105 of adherent PECs in wells of a 96-well 
round-bottomed microtiter plate, each containing 
0.2 ml of 5% FCS modified MEM at 37 °C for 24 h fol-
lowed by an additional 24 h-incubation for 3H-TdR up-
take (1 μCi/ml). Radioactivity in the cells per well 
was counted using a scintillation counter. Anti-tumor 
activity of peritoneal macrophages was estimated 
by subtracting the 3H-TdR uptake by peritoneal mac-
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rophages from that by both peritoneal macrophages 
and MH134 cells. Anti-tumor activity of gelatin was es-
timated using liquid form gelatin instead of peritoneal 
macrophages.
Anti-tumor activity of gelatins in vivo. In all ex-
periments, gelatin was administered 2 days after 
tumor cell challenge. When MH134 or Colon 26 tu-
mor cells (1 x 105/mouse) were inoculated i. p., 
6.25 or 12.5 mg of PS gelatin was administered i. p. 
everyday until the mice died. When MH134 tumor 
cells (1 x 104/mouse) were inoculated subcutane-
ously (s. c.), 12.5 mg of PS gelatin was administered 
i.p. everyday until the mice died. When MH134 tu-
mor cells (1 x 104/mouse) were inoculated i. p., 
12.5 mg of PS, BB or BS gelatin was administered s. c. 
or 2.5 ml of PS gelatin solution (12.5 mg/ml) was done 
per os (p. o.) everyday until the mice died.
Retention period of PS gelatin injected i. p. 
Three mice (C3H/HeN), each were injected with 0.5 ml 
of PBS or 12.5 mg (25 mg/ml) of PS gelatin i. p. After 
5 min, 8 ml of PBS was injected into the peritoneal 
cavity, and the PBS was collected. The concentra-
tion of protein in the PBS was determined by staining 
the protein with Quick StartTM Bradford Dye Reagent 
(BIO-RAD) and measuring the optical density (OD595) 
using Ultraspec 3000 (Pharmacia Biotech). Dilution 
of PS gelatin was used to construct the standard curve 
for the protein assay.
Statistics.  Dif ference between 2 groups 
was evalua ted using two-tailed Student’s t-test 
or Welch’s test unless otherwise noted. Difference 
between 2 groups in tumor sizes was evaluated using 
Mann — Whitney test because each population of tu-
mor size did not show statistic normal distribution. 
Difference between 2 groups in survival was evalu-
ated using Log-rank test. P values of 5% or less were 
considered statistically significant.
RESULTS
Effect of gelatin on proliferation of murine 
tumor cells in vitro. Fig. 1 shows that at least 
3.75 mg/ml of PS and BS gelatins suppressed prolife-
ration of MH134 cells (Fig. 1, a) or Colon 26 cells 
(Fig. 1, c) in vitro and that the anti-tumor effect 
of PS gelatin was partially cytocidal (Fig. 1, b, d).
Effect of PS gelatin administered i. p. on the sur-
vival of mice i. p. inoculated with MH134 or Colon 
26 tumor cells. Fig. 2, a shows that intraperitoneal 
daily administration of 12.5 mg of PS gelatin prolonged 
the survival of mice inoculated with MH134 tumor cells 
i. p. and produced tumor-free mice. Fig. 2, b shows that 
i. p. daily administration of 6.25 or 12.5 mg of PS gela-
tin prolonged the survival of mice inoculated with Colon 
26 tumor cells.
Effect of i. p. administered PS gelatin on growth 
of subcutaneous MH134 tumor and the survival 
of mice bearing the tumor was not shown since there 
was no difference between control and experimental 
groups.
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Fig. 1. Anti-tumor activity of three kinds of gelatin in vitro. MH134 
(a) or Colon 26 (c) cells (5 x 103/well) were incubated with the in-
dicated concentration of PS ( ), BS ( ) or BB ( ) gelatin in wells 
of a 96-well round-bottomed microtiter plate, each containing 
0.2 ml of 5% FBS modified MEM at 37 °C for 48 h. Then 1 μCi/ml 
of 3H-TdR was added to the wells followed by 7 h-incubation. MH134 
(b) or Colon 26 (d) cells labeled with 3H-UdR (5 x 103/well) were in-
cubated with the indicated concentration of PS ( ), BS ( ) or BB ( ) 
gelatin in wells of a 96-well round-bottomed microtiter plate, each 
containing 0.2 ml of 5% FBS modified MEM at 37 °C for 24 h. The ra-
dioactivity in 0.1 ml of the supernatant was counted
Required duration of contact of tumor cells 
with PS gelatin to exert its anti-tumor activity. 
As it could be seen from Table, it required as short 
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as 5 min for PS gelatin to exert its anti-tumor ac-
tivity. Fig. 3 shows that after the 5 min-incubation 
of MH134 cells with or without PS gelatin, 3H-TdR up-
take by the cells treated with it decreased and without 
it increased with the lapse of time.
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Fig. 2. Effect of intraperitoneal injection of PS gelatin 
on the survival of mice bearing MH134 and Colon 26 tumors. 
MH134 (a) or Colon 26 (b) tumor cells (1 x 105) were inocu-
lated i. p. on day 0 into mice. On day 2, 6.25 mg (n = 6) ( ) 
or 12.5 mg (n = 11) ( ) of PS gelatin was administered i. p., to-
gether with control group without PS gelatin (n =12) ( ). Then 
the same treatment was done everyday until those mice died. 
a,  vs  : p < 0.002,  vs : not significant (NS). b,  vs : p < 0.02, 
 vs : p < 0.05
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Fig. 3. PS gelatin exclusively suppresses the proliferation of tumor 
cells. MH 134 cells (5 x 103/well) were incubated with ( ) or without 
( ) 15 mg/ml of PS gelatin in a 96-well round-bottomed microtiter 
plate, each containing 0.2 ml of 5% FBS modified MEM at 37 °C 
for 5 min, and they were washed with 0.2 ml of PBS twice. Then 
they were incubated in the same manner without PS gelatin 
for the indicated period. 3H-TdR (1 μCi/ml) was added to each 
well 7 h before completion of the incubation. *NS from control ( ). 
** Significant from control ( ) at p < 0.001.
Retention of i. p. injected PS gelatin in the peri-
toneal cavity. Fig. 4 shows that there was an ap-
preciable amount of protein in the peritoneal cavi ty 
5 min after i. p. injection of PBS (0.5 ml) and that 
a larger amount of protein was detected 5 min after 
i. p. injection of PS gelatin (12.5 mg) than i. p. injection 
of PBS (0.5 ml).
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Fig. 4. Retention of PS gelatin injected i. p. in the perito-
neal cavity. Three mice, each was injected with or without 
12.5 mg/ 0.5 ml of PS gelatin. After 5 min, the peritoneal cavi ty 
was lavaged with 8 ml of PBS. The concentration of protein 
in the collected PBS was measured
*p = 0.0549 (two tailed t-test), p = 0.0274 (one tailed t-test).
Anti-tumor activity of peritoneal macrophages 
which were elicited by intraperitoneal administra-
tion of PS gelatin. Fig. 5 shows that mPMs elicited 
by thioglycollate injection suppressed 3H-TdR uptake 
by MH134 cells as compared with medium alone. 
mPMs elicited by PS gelatin injection suppressed 
3H-TdR uptake by MH134 cells more strongly than 
those elicited by thioglycollate injection.
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Fig. 5. Anti-tumor activity of mPMs which were elicited by in-
traperitoneal injection of PS gelatin. Three mice, each were 
injected with 3 ml of 3%thioglycollate medium i. p. on day or with 
12.5 mg of PS gelatin on day 0, 1, 2. On day 3, PECs were 
collected. MH134 cells (5 x 103/well) were incubated with 
1 x 105 of the indicated mPMs in wells of a 96-well round-bot-
tomed microtiter plate, each containing 0. 2 ml of 5% FCS modi-
fied MEM at 37 °C for 24 h followed by additional 24 h-incubation 
for 3H-TdR uptake (1 μCi/ml)
Effect of subcutaneously administered gela-
tin on the survival of mice i. p. inoculated with 
MH134 tumor cells. Fig. 6, a shows that subcutane-
ously administered PS gelatin did not affect the sur-
vival of mice with intraperitoneal MH134 tumor. Fig. 6, b 
shows that subcutaneously administered BB gelatin 
tended to prolong the survival. Fig. 6, c shows that 
subcutaneously administered BS gelatin significantly 
prolonged the survival.
The data on the effect of orally administered 
PS gelatin on the survival of mice i. p. inoculated 
with MH134 tumor cells are not shown since there 
was no difference between control and experimental 
groups.
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Fig. 6. Effect of s. c. administration of 3 kinds of gelatin 
on survival of mice inoculated with MH134 tumor cells i. p. 
MH134 tumor cells (1 x 104) were inoculated i.p. into each mouse. 
PS (a, ) (n = 10), BB (b, ) (n = 11), BS (c, ) (n = 11) gelatin 
(12.5 mg/0.5 ml of PBS) or 0.5 ml of PBS (a, b, c, ) (a, n = 9, 
b, n = 10, c, n = 9) was administered s. c. 2 days after the tumor 
inoculation. Then the same treatment was done everyday until 
those mice died. a: NS, b: NS, c: p < 0.05
Table. Required period of contact between tumor cells and PS gelatin
Exp Incubation time (min)
PS gelatin 
(mg/ml)
3H-TdR uptake 
by MH 134 cells 
(dpm/well)
1 15 0 3042 ± 243
15 715 ± 178
360 0 2996 ± 326
15 591 ± 126
2 5 0 1711 ± 214
15 797 ± 84
3 0 0 8109 ± 683
15 7636 ± 398
Notes: MH134 cells (5 x 103/well) were incubated with 0 or 15 mg/ml 
of PS gelatin in a 96-well round-bottomed microtiter plate, each containing 
0.2 ml of 5% FBS modified MEM at 37 °C for the indicated duration, and they 
were washed with 0.2 ml of PBS twice. Then they were incubated in the same 
manner without PS gelatin for 48 h (Exp. 1 & 2) or 72 h (Exp. 3). 3H-TdR 
(1 μCi/ml) was added to each well 7 h before completion of the incubation.
DISCUSSION
The present  study invest igated whether 
or not PS gelatin administered i. p., s. c., or p. o. 
controlled growth of tumor in vivo. PS gelatin exerted 
a stronger in vitro anti-tumor activity than BB or BS ge-
latin, mainly cytostatic toward 2 kinds of tumor cell 
lines. It remains to be solved what causes these diffe-
rent anti-tumor activity among such gelatins. It is well 
known that gelatins have a common amino acid 
sequence, i. e., glycine-X-Y. At present, we suppose 
that different anti-tumor activities of gelatins are at-
tributed to different X and Y. PS gelatin administered 
i. p. prolonged the survival of mice bearing intraperi-
toneal MH134 or Colon 26 tumor. Colon 26 tumor cells 
formed a lesion similar to clinical state, what is called 
dissemination though MH134 tumor cells grew as sing-
le cells in the peritoneal cavity (data not shown). Ad-
ministration of PS gelatin started 2 days after the tumor 
cell inoculation and was continued everyday until death 
of the mice. It is not clear whether or not this schedule 
of administration is appropriate in order to evaluate 
the anti-tumor activity of this gelatin from a clinical view-
point. In any case, it has become clear that PS gelatin 
exerts an anti-tumor activity in vivo as well as in vitro. 
Previously, we reported that PS gelatin stimulated 
peritoneal macrophages in vitro to secrete TNF-α [2, 
5], and to obtain anti-tumor activity which was exerted 
in vivo as well as in vitro [5]. In the present study, peri-
toneal macrophages which exerted anti-tumor activity 
in vitro had been induced by i. p. injection of PS gelatin. 
MH134 tumor cells inoculated s. c. was not affected 
by PS gelatin administered i. p. (data not shown). 
This result may suggest that anti-tumor peritoneal 
macrophages induced by i. p. injection of PS gelatin 
did not accumulate to the cutaneous region and that 
the amount of TNF-α secreted by peritoneal mac-
rophages stimulated with PS gelatin was not enough 
to suppress tumor proliferation. The previous study 
showed that peritoneal macrophages stimulated with 
PS gelatin secreted an appreciable amount of TNF-α, 
but the TNF-α did not participate in the anti-tumor 
activity of the culture supernatant in vitro [5].
Alternatively, these in vivo experiments suggest 
the following possibilities. One is that tumor cells 
inoculated i. p. were attacked directly by PS gelatin 
administered i. p. Another is that anti-tumor peritoneal 
macrophages induced by PS gelatin administered i. p. 
exert anti-tumor activity in situ. Retention of PS gelatin 
administered i. p. in the peritoneal cavity was exa-
mined. Protein of approximately 12.5 mg remained 
in the peritoneal cavity at least 5 min after the admi-
nistration. If the protein is PS gelatin, this concentration 
of PS gelatin (approximately 12.5 mg/ml) was enough 
to suppress tumor proliferation in vitro. So there 
is a little fluid containing proteins, less than 1 ml, 
in normal peritoneal cavity. However, a possibility can-
not be excluded that detected protein is not PS gelatin 
but proteins in the exudate elicited with i. p. adminis-
tration of PS gelatin. On the other hand, it was exa-
mined how long contact with tumor cells was required 
for PS gelatin to exert its anti-tumor activity. The con-
tact for several seconds was not enough. It required 
at least 5 min. These results suggest a possibility 
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that tumor cells inoculated i. p. are directly attacked 
by PS gelatin administered i. p. In conclusion, results 
suggest that the anti-tumor macrophages as well 
as PS gelatin attack tumor cells inoculated i. p.
In order to examine anti-tumor effect of systemic 
administration of gelatin, intraperitoneal administration 
of PS gelatin was conducted. However, s. c. inoculated 
tumor cells were not affected. Inversely effect of sub-
cutaneous administration of BB, BS or PS gelatin on tu-
mor cells inoculated i. p. was examined. BS gelatin 
administered s. c. exerted a statistically significant 
anti-tumor activity but not PS or BB gelatin. However, 
the anti-tumor activity was weaker than that of PS gela-
tin administered i. p. to tumor cells inoculated i. p. 
The present study showed that BS gelatin exerted 
moderate direct anti-tumor effect in vitro among BB, 
BS and PS gelatins. The previous study, however, 
showed that BS gelatin did not induce cytokine secre-
tion by peritoneal macrophages [2]. In order to clarify 
the mechanism of this strange result, it should be in-
vestigated how gelatin is digested and how it or its di-
gested products are transferred.
PS gelatin administered orally did not exert anti-
tumor activity to intraperitoneal MH134 tumor. PS gela-
tin administered orally may be digested to be inactive 
amino acids and/or peptides.
There has been no effective cure for peritoneal 
dissemination, e. g., gastric cancer or ovarian tu-
mors. Cisplatin, (SP-4-2)-Diamminedichloroplatinum 
and its derivatives are administered intravenously 
or i. p. to treat these diseases [6–11]. However, they 
have exerted partial effects. This study shows that 
PS gelatin administered i. p. can partially control 
intraperitoneal tumor. It is well known that gelatin 
[12–14] as well as collagen [15–17] possesses low im-
munogenicity. Therefore i. p. application of PS gelatin 
may be effective for controlling peritoneal dissemina-
tion in collaboration with chemotherapeutic agents.
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